Changing the finish line: Syneos talks bringing payer, patient voice into drug development

By Melissa Fassbender contact

- Last updated on GMT

The drug development “finish line” is not regulatory approval, says Syenos Health chief scientific officer Judith Ng-Cashin, MD, who discusses bringing the payer and patient voice into the process.

Outsourcing-Pharma sat down with Ng-Chasin at the Syneos Health headquarters in Raleigh, NC ahead of the DIA 2018 Global Annual Meeting, which takes place next week.

The conference is a “great space”​ for conversation and neutral safe harbor for sponsors, contract research organizations (CROs), regulators, and payers, said Ng-Chasin, who was elected to the DIA Board of Directors in 2017.

“I think that element we talk about on the [DIA] board of involving the payer voice now at DIA is really starting to evolve as a trend,”​ she told us – noting that while it is not a new trend, it continues to affect how companies develop new therapies.

“Your finish line isn’t regulatory approval – your finish line is past market authority and really about reaching the right patients and also appropriate reimbursement,”​ she explained. For these reasons, among others, Ng-Chasin said bringing the payer and patient voice into the mix is important.

“People are starting to change their thinking,”​ she added, specifically about endpoints and the definition of clinically meaningful impact.

“Sometimes it’s ‘I don’t need to walk for six minutes, I need to be able to get from my bed to the bathroom by myself’ – that’s meaningful.”

Watch the above video to hear more of Ng-Chasin’s comments on DIA and the evolving drug development industry.

Related news

Show more

Related products

show more

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Related suppliers

Follow us

Products

View more

Webinars